Shalby Medtech CEO Deepak Anand resigns to move abroad
Deepak Anand resigns as CEO of Shalby Medtech Limited, a subsidiary of Shalby Limited, effective September 4, 2026. He cited personal reasons for moving abroad as the sole cause for his exit. Shalby Limited confirmed no other material factors influenced the decision.

*this image is generated using AI for illustrative purposes only.
Shalby Limited disclosed that Deepak Anand has tendered his resignation from the position of Chief Executive Officer at Shalby Medtech Limited, a wholly-owned subsidiary. The resignation is effective from the close of business hours on September 4, 2026.
The company informed the National Stock Exchange of India Ltd and BSE Limited on August 18, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In his resignation letter dated August 18, 2026, Anand cited personal reasons as the sole driver for his decision to move abroad.
Resignation Details
Shalby Limited confirmed that there are no other material reasons for Anand's departure beyond those stated in his letter. He assured full cooperation during the transition period to ensure an orderly handover of responsibilities.
| Particulars | Details |
|---|---|
| Resigned Officer | Deepak Anand |
| Designation | Chief Executive Officer, Shalby Medtech Limited |
| Effective Date | September 4, 2026 |
| Reason | Personal reasons (moving abroad) |
| Other Material Reasons | None |
Tushar Shah, AVP and Company Secretary at Shalby Limited, signed the disclosure. The company requested the stock exchanges to update their records accordingly.
Historical Stock Returns for Shalby
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.50% | -5.85% | -7.07% | -4.48% | -24.58% | -20.52% |
Has Shalby Limited identified an internal successor or initiated a search for a new CEO for Shalby Medtech?
How might this leadership transition impact Shalby Medtech's ongoing product development pipelines and regulatory approvals?
Will Deepak Anand's departure affect the strategic partnership dynamics between Shalby Hospitals and its medtech subsidiary?


































